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Abstract
Background: Exposure to phthalates, a class of endocrine disrupting chemicals, is ubiquitous. We examined the
association of urinary phthalate metabolite concentrations during pregnancy with maternal blood pressure and risk
of pregnancy-induced hypertensive diseases.
Methods: We used data from the Health Outcomes and Measures of the Environment Study, a prospective birth
cohort of low-risk pregnant women recruited between March 2003 and January 2006. We analyzed maternal urine
samples collected at 16 and 26 weeks gestation for 9 phthalate monoester metabolites reflecting exposure to 6
phthalate diesters. Outcomes included maternal blood pressure at <20 and ≥20 weeks gestation and pregnancy
induced hypertensive diseases (gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome).
Results: Data were available for 369 women who gave birth to singleton, live-born infants without congenital
anomalies. Of the phthalate metabolites evaluated, only mono-benzyl phthalate (MBzP) concentrations were
significantly associated with maternal diastolic blood pressure at <20 weeks gestation. Women in the third MBzP
tercile at 16 weeks gestation had diastolic blood pressure 2.2 (95 % CI: 0.5–3.9) mm Hg higher at <20 weeks
gestation and 2.8 (95 % CI: 0.9–4.7) mm Hg higher at ≥20 weeks gestation compared to women in the first tercile.
Compared to women in the first tercile, women in the top MBzP tercile at 16 weeks had an increased risk of
developing pregnancy-induced hypertensive diseases (RR = 2.92, 95 % CI 1.15–7.41, p-value for trend = 0.01). MBzP
concentrations at 26 weeks gestation were not as strongly associated with blood pressure at ≥20 weeks gestation
or risk of pregnancy-induced hypertensive diseases.
Conclusion: This study suggests that maternal urinary MBzP concentrations may be associated with increased
diastolic blood pressure and risk of pregnancy-induced hypertensive diseases.
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Background
Recent studies have suggested that exposure to phthalic
acid diesters (i.e., phthalates) may be associated with ele-
vated blood pressure and increased risk of cardiovascular
disease. A cross-sectional analysis of the National Health
and Nutrition Examination Survey suggested that in-
creased urinary phthalate concentrations are associated
with higher blood pressure in children [1]. Additionally,
a cross-sectional study of older adults in Sweden found
that increased serum concentrations of monobenzyl
phthalate (MBzP) were associated with several cardio-
vascular risk factors [2]. If phthalate exposure impacts
blood pressure or cardiovascular risk, it may also impact
gestational blood pressure and preeclampsia risk.
Women of reproductive age in the United States have
almost ubiquitous exposure to phthalates [3, 4]. Phthal-
ate diesters can be found in polyvinyl chloride plastics,
personal care products (e.g., shampoo, soap, perfume),
flooring, adhesives, and food processing equipment. Ex-
posure to phthalates can occur through dermal absorp-
tion, ingestion, or inhalation. Phthalates are metabolized
into their respective monoester metabolites after
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exposure and then conjugated before being excreted in
the urine; thus, urinary phthalate monoester metabolites
can be used as sensitive and specific biomarkers of ex-
posure [5].
While the exact mechanism by which phthalate expos-
ure may influence cardiovascular health is unknown,
phthalates are hypothesized to be endocrine disruptors
that affect the action and metabolism of androgens, cor-
tisol, and thyroid hormones [6–8]. Phthalates may also
cause a pro-inflammatory response and increased oxida-
tive stress [9]. This latter mechanism is implicated as a
possible etiology for preeclampsia. Thus, we sought to
investigate the relationship of maternal urinary phthalate
concentrations during gestation with maternal blood
pressure and pregnancy-induced hypertensive diseases,
such as preeclampsia. We hypothesized that increased
maternal urinary phthalate levels would be associated with
increased maternal blood pressure and risk of pregnancy-
induced hypertensive diseases (gestational hypertension,
preeclampsia, eclampsia, and HELLP syndrome).
Methods
This study is an analysis of data from The Health Out-
comes and Measures of the Environment (HOME)
Study, a prospective pregnancy and birth cohort study
designed to examine the associations of environmental
chemicals with maternal and child health outcomes. The
HOME Study recruited pregnant women from 2003 to
2006 who were ≥ 18 years of age, 16 ± 3 weeks of gesta-
tion, and living in the Cincinnati, OH area in homes
built before 1978 [10]. Women were recruited from nine
prenatal clinics associated with three hospitals. Women
with HIV, or those taking medications for seizures or
thyroid disorders were excluded as one of the primary
outcomes of the original HOME Study was neurodeve-
lopment. In total, 468 pregnant women enrolled in the
HOME Study. The study was approved by the institu-
tional review boards of Cincinnati Children’s Hospital
Medical Center, cooperating delivery hospitals, and the
Centers for Disease Control and Prevention (CDC).
This analysis included women who were still par-
ticipating in the study at the time of delivery and
who delivered a live singleton (n = 389). We excluded
two women whose offspring had congenital or chromo-
somal abnormalities as some fetal conditions (i.e. hydrops)
can predispose women to hypertension in pregnancy. Fi-
nally, we excluded 18 women who were missing exposure
(n = 5), outcome (n = 4), or covariate (n = 9) data, leaving
369 pregnancies for our primary analyses.
The primary outcome we evaluated was the first two
diastolic and systolic blood pressure measurements in
the woman’s medical chart in early-mid pregnancy
(<20 weeks). We selected this as the primary outcome
since maternal blood pressure in the first and early
second trimester affects placentation and is known to
predict preeclampsia risk [11, 12]. Additional outcomes
included the two highest blood pressures after 20 weeks
gestation and physician diagnosed pregnancy-induced
hypertensive diseases, including gestational hyperten-
sion, preeclampsia, HELLP syndrome, and eclampsia. As
part of the original HOME Study data collection, partici-
pants’ medical charts were reviewed after delivery, and
all relevant pregnancy complications were abstracted.
Trained research assistants abstracted diastolic and sys-
tolic blood pressures and medical conditions from med-
ical records. The original study protocol involved
abstracting the first two blood pressures available in the
medical record (<20 weeks) and the two highest blood
pressures after 20 weeks. Additional blood pressure data
at <20 or after 20 weeks was not available for this
analysis.
Study participants were defined as having gestational
hypertension, preeclampsia, eclampsia or HELLP syn-
drome if their provider made the clinical diagnosis and
documented it in their medical record. Additionally, we
considered a woman to have gestational hypertension if
either of her two blood pressure measurements at ≥
20 weeks met at least one of the following conditions: el-
evated systolic blood pressure (>140 mm Hg) at both
measurements, elevated diastolic blood pressure
(>90 mm Hg) at both measurements, or elevated systolic
blood pressure at one measurement and elevated dia-
stolic blood pressure at the other measurement or vice
versa. A woman was considered to have a pregnancy-
induced hypertensive disease if she had one or more of
the following diagnoses: gestational hypertension, pre-
eclampsia, eclampsia or HELLP syndrome. Women with
two blood pressures ≥140/90 prior to 20 weeks (chronic
hypertension) could still be considered to have a
pregnancy-induced hypertensive disease if they devel-
oped preeclampsia, eclampsia or HELLP (i.e. superim-
posed preeclampsia).
We collected covariate information during home visits
~ 20 weeks gestation and at the prenatal visit at the time
women completed their glucose tolerance test
(~26 weeks gestation). Study staff surveyed participants’
about their socio-demographic status, including mater-
nal age, race, income, marital status and insurance status
using standardized interviews. Additionally, we obtained
data on parity and body mass index (BMI) at 16 weeks
from the medical record. We measured serum cotinine,
a biomarker of tobacco smoke exposure, and blood lead
in samples collected at approximately 16 and 26 weeks
gestation. We also asked women if they had ever taken
medication for high blood pressure.
Maternal urinary phthalate metabolite concentrations
were obtained from spot samples at an average of 16
(range: 10–23) and 26 (range: 19–35) weeks gestation.
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Less than 1 % (n = 3) of the 16 week samples were col-
lected after 20 weeks of gestation. We collected urine
into polypropylene specimen cups that had been lot
tested for phthalate contaminants, refrigerated until pro-
cessing, and stored at or below −20 °C until chemical
analysis. Urinary phthalate metabolites were measured
using previously described analytic methods [13]. We
measured nine phthalate monoester metabolites that
reflected exposure to six parent diesters [5]. For phthal-
ate metabolite levels reported as below level of detection
(LOD), a value of LOD/√2 was used for analytic pur-
poses. We summed the molar concentrations of DEHP
(∑DEHP) and di-butyl phthalate (∑DBP) monoester me-
tabolites. Thus, we examined five different phthalates in
the analysis: monoethyl phthalate (MEP), mono-3-
carboxylpropyl phthalate (MCPP), monobenzyl phthalate
(MBzP), ∑DEHP, and ∑DBP. Phthalate metabolite con-
centrations were creatinine-normalized to account for
maternal hydration by dividing urinary phthalate metab-
olite concentrations by urinary creatinine concentrations
and multiplying this by 100.
Statistical analysis
We adjusted for maternal race, age at delivery, house-
hold income, education, marital status, serum cotinine
concentrations, parity, BMI at 16 weeks gestation, and
self-reported use of medications for high blood pressure
in all of our statistical models. We examined serum lead
concentrations as a confounder, but it did not substan-
tially change our estimates, so we did not include it in
our final models. Our models examining continuous
blood pressure measurements during pregnancy also in-
clude the week of gestation to account for changes in
blood pressure across the course of pregnancy. We used
linear mixed models with an unstructured covariance
matrix and random intercept to estimate the association
between maternal urinary phthalate metabolite concen-
trations at 16 weeks and the two repeated maternal
blood pressure measures collected at <20 weeks gesta-
tion. We examined the association between phthalate
metabolite concentrations at 16 and 26 weeks, as well as
their average, and the two highest blood pressures at
≥20 weeks gestation using these same models. Finally,
we examined phthalate metabolite concentrations at 16
and 26 weeks, as well as their average, and the risk of
pregnancy-induced hypertensive diseases using Poisson
regression. We examined both continuous log10-trans-
formed creatinine-normalized urinary phthalate metab-
olite concentrations, as well as terciles. We calculated
robust standard errors in all of our analyses.
Results
On average, study participants were well-educated (50 %
with at least a bachelor’s degree), married (66 %), and
Caucasian (62 %) (Table 1). The average age of partici-
pants at delivery was 29.5 years (standard deviation =
5.8 years). All women had detectable levels of at least
one phthalate metabolite in their urine; the frequency of
detection at 16 or 26 weeks ranged from 75 % (MEHP,
level of detection (LOD) 1.2 ng/mL) to 100 % (MEP,
LOD 0.5 ng/mL). Most urine phthalate metabolite con-
centrations at 16 weeks gestation (i.e., baseline) were
similar among women who remained enrolled in the
study and those who dropped out prior to delivery;
ΣDBP (31 vs. 27 μg/g Cr), ΣDEHP (99 vs. 89 μg/g Cr),
MCPP (2.5 vs. 2.7 μg/g Cr), and MBzP (9.2 vs. 11.2 μg/g
Cr) . MEP (139 vs. 187 μg/g Cr) concentrations were
slightly higher among women who dropped out prior to
delivery.
The average systolic and diastolic blood pressures were
110 (SD: 13) and 66 (SD: 10) mm Hg, respectively, and
were first measured at an average of 11 weeks gestation
(range 4–20). Thirteen women had blood pressures con-
sistent with chronic hypertension (2 blood pressures ≥
140/90 before 20 weeks gestation). A total of 34 (9.2 %)
women developed at least one the following: gestational
hypertension (n = 13, 4 %), preeclampsia (n = 21, 6 %), or
HELLP syndrome (n = 2, 1 %). No women were diag-
nosed with eclampsia. Both of the women with HELLP
were also diagnosed with preeclampsia. The women who
developed pregnancy-induced hypertensive disorders
were most often non-white, overweight or obese, nul-
liparous, or reported previously taking high blood pres-
sure medications (Table 1).
Increasing urinary MBzP concentrations at 16 weeks
gestation were significantly associated with increased
diastolic blood pressure at <20 weeks gestation (Table 2).
Women in the third MBzP tercile at 16 weeks gestation
had diastolic blood pressure 2.2 (95 % CI: 0.5-3.9) mm
Hg higher at <20 weeks gestation and 2.8 (95 % CI: 0.9-
4.7) mm Hg higher at ≥20 weeks gestation compared to
women in the first tercile (Figs. 1 and 2, p-value for
trend 0.01 and <0.01 respectively). No other phthalate
metabolites were significantly associated with blood pres-
sure measures before or after 20 weeks gestation.
We observed a trend suggesting increased risk of preg-
nancy induced hypertensive disease with higher 16 week,
26 week, or average urinary MBzP concentrations (p-
values for trend = 0.01, 0.12, and 0.04, respectively) . The
association was strongest for the 16 week urinary MBzP
concentrations. Women in the 3rd tercile of urinary
MBzP concentrations were almost three times as likely
to have a pregnancy-induced hypertensive disease com-
pared to women in the lowest tercile (RR 2.92; 95 % CI
1.15-7.41) (Table 3).
We performed several sensitivity analyses to examine
the robustness of our MBzP associations to various as-
sumptions. First, given the potential for urinary
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Table 1 Number of women with pregnancy-induced hypertensive disorders (cases include gestational hypertension, preeclampsia,
HELLP syndrome or eclampsia), median (25th, 75th) urinary phthalate metabolite concentrations (μg/g creatinine), and mean (SD)
systolic and diastolic blood pressures (mm Hg) at <20 weeks pregnancy according to covariates among HOME Study women*
Demographic or Perinatal Characteristic Cases N (%)a MEP MBzP MCPP ∑DBP ∑DEHP SBP DBP
Overall 34 369 (9) 132 (70, 285) 9 (5.4, 16) 2.2 (1.6, 3.3) 31 (22, 45) 83 (53, 159) 110 (13) 66 (10)
Race
White 14 230 (6) 127 (64, 247) 8.2 (5, 14) 2.3 (1.7, 3.4) 31 (22, 44) 98 (59, 191) 111 (12) 68 (10)
Non-White 20 139 (14) 139 (85, 344) 11 (6.4, 21) 1.9 (1.2, 2.9) 32 (21, 51) 74 (48, 125) 109 (13) 63 (10)
Maternal Age at Delivery (years)
<25 12 88 (14) 133 (79, 292) 13 (7.5, 22) 2 (1.3, 3.2) 34 (21, 56) 66 (47, 124) 109 (12) 63 (10)
25- < 35 18 220 (8) 132 (65, 284) 8.3 (4.9, 15) 2.3 (1.7, 3.3) 30 (20, 43) 94 (58, 180) 111 (13) 67 (10)
35+ 4 61 (7) 139 (64, 260) 8 (5.3, 12) 2.1 (1.6, 2.9) 34 (26, 45) 100 (58, 177) 109 (13) 70 (9)
Maternal Education
Completed College 14 186 (8) 126 (55, 254) 7 (4.8, 12) 2.3 (1.7, 3.3) 30 (21, 42) 98 (58, 197) 111 (13) 68 (9)
Some College 8 94 (9) 135 (71, 303) 11 (5.9, 15) 2.3 (1.6, 3.3) 33 (22, 47) 80 (58, 148) 109 (13) 65 (10)
High School or Less 12 89 (13) 148 (92, 344) 14 (7.9, 24) 2 (1.2, 2.8) 34 (22, 58) 69 (48, 125) 111 (12) 63 (11)
Marital Status
Married 18 243 (7) 128 (63, 264) 8 (5, 13) 2.3 (1.7, 3.3) 31 (22, 43) 96 (59, 193) 110 (13) 68 (10)
Unmarried-Living Together 8 53 (15) 168 (103, 458) 11 (6.6, 22) 1.8 (1.1, 3.2) 32 (20, 57) 74 (48, 142) 112 (12) 65 (9)
Unmarried-Living Alone 8 73 (11) 131 (75, 285) 13 (7.4, 22) 1.9 (1.3, 2.8) 34 (21, 54) 66 (49, 125) 108 (11) 62 (10)
Household Income
$80,000+ 4 102 (4) 119 (64, 247) 7.2 (4.9, 12) 2.3 (1.7, 3.3) 30 (23, 44) 96 (61, 181) 109 (13) 68 (9)
$40-80,000 14 124 (11) 121 (61, 268) 7.9 (4.6, 12) 2.3 (1.7, 3.2) 31 (20, 40) 97 (58, 205) 111 (12) 68 (9)
$20-40,000 4 63 (6) 147 (70, 336) 9.9 (5.6, 15) 1.7 (1.2, 3.4) 30 (19, 51) 84 (46, 156) 110 (14) 65 (11)
<$20,000 12 80 (15) 148 (88, 347) 15 (9.9, 29) 2.2 (1.4, 3) 36 (23, 58) 73 (48, 115) 109 (11) 63 (10)
Maternal Tobacco Smoke Exposure: Serum Cotinine (ng/mL)
None: < <0.015 9 137 (7) 111 (56, 264) 6.9 (4.4, 12) 2.2 (1.7, 3.2) 30 (19, 42) 86 (55, 167) 111 (13) 69 (10)
Secondhand: 0.015-3 21 193 (11) 134 (74, 274) 11 (6.1, 17) 2.2 (1.5, 3.3) 32 (22, 47) 82 (55, 162) 110 (12) 65 (10)
Active: >3 4 39 (10) 173 (100, 472) 13 (7.9, 21) 2.3 (1.5, 3.3) 36 (23, 54) 74 (49, 139) 109 (12) 61 (10)
Maternal BMI at 16 weeks (kg/m2)
<25 6 157 (4) 131 (74, 286) 8.8 (5.2, 15) 2.1 (1.6, 3.3) 31 (23, 43) 83 (54, 153) 107 (13) 65 (11)
25- < 30 12 120 (10) 133 (71, 271) 8.2 (5.1, 13) 2.2 (1.5, 3.3) 29 (20, 42) 87 (48, 175) 111 (12) 67 (9)
30+ 16 92 (17) 139 (66, 328) 11 (6.3, 21) 2.3 (1.6, 3.1) 36 (24, 57) 81 (58, 150) 113 (12) 68 (10)
Parity
0 21 166 (13) 140 (83, 319) 7.9 (4.9, 15) 2.3 (1.6, 3.4) 32 (21, 46) 97 (53, 167) 110 (13) 66 (10)
1 4 115 (3) 122 (65, 218) 11 (6.4, 15) 2.3 (1.6, 3.3) 32 (22, 47) 87 (55, 193) 111 (11) 67 (11)
2+ 9 88 (10) 130 (63, 305) 10 (5.3, 17) 1.9 (1.3, 2.8) 31 (21, 41) 74 (49, 129) 110 (13) 66 (10)
Medication for High Blood Pressure
No 28 349 (8) 131 (70, 283) 9.3 (5.4, 16) 2.2 (1.6, 3.3) 32 (22, 45) 86 (52, 162) 109 (12) 66 (10)
Yes 6 20 (30) 192 (89, 364) 8.2 (4.4, 13) 1.9 (1.4, 2.4) 30 (22, 50) 70 (56, 100) 120 (13) 76 (13)
a-Row percent
*∑DBP is the weighted molar sum of MnBP (molecular weight = 222 g/mol) and MiBP (molecular weight = 222 g/mol) concentrations expressed in concentrations
of μg/g creatinine. We multiplied the molar sum (μmol/g creatinine) of MnBP and MiBP by the molecular weight of MnBP (222 g/mol). ∑DEHP is the weighted
molar sum of MEHP (molecular weight = 272), MEHHP (molecular weight = 294), MEOHP (molecular weight = 292), and MECPP (molecular weight = 308)
concentrations expressed in concentrations of μg/g creatinine. We multiplied the molar sum (μmol/g creatinine) of MEHP, MEHHP, MEOHP, and MECPP by the
molecular weight of MECPP (308 g/mol)
The phthalate concentrations are the average of the two log10-transformed concentrations from 16 and 26 weeks gestation
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phthalate concentrations to be significantly affected by
renal function, we excluded women with low (<20 mg/
dL) or high (>300 mg/dL) 16 week urinary creatinine
concentrations (n = 28). The association between MBzP
concentrations and maternal diastolic blood pressure
<20 weeks did not change appreciably after this exclu-
sion. Second, we accounted for urine dilution by adjust-
ing for creatinine concentrations in our statistical
models of 16 and 26 week urinary phthalate metabolites,
rather than creatinine-normalizing urinary phthalate
concentrations; again our results were relatively un-
changed. Third, we also analyzed the data stratifying for
the timing of blood pressure measurements prior to
20 weeks gestation relative to the timing of urine sample
collection. We found a consistent association between
MBzP concentrations and increased diastolic blood pres-
sure at <20 weeks of pregnancy regardless of whether
the blood pressure measurements were obtained before
or after the urine sample collection. Finally, we excluded
women who reported previously using medication for
high blood pressure (n = 20) and our results were
unchanged.
Discussion
In this prospective, longitudinal pregnancy and birth co-
hort, we found that urinary MBzP concentrations in
early-mid pregnancy were significantly associated with
increased diastolic blood pressure and an increased risk
of pregnancy-induced hypertensive diseases. The associ-
ations between urinary MBzP concentrations and dia-
stolic blood pressure in this study are modest, but the
population impact could be substantial because exposure
to the parent compound of this metabolite, butyl benzyl
phthalate, is ubiquitous in U.S. women [4].
A study using data from the National Health and Nu-
trition Examination Survey (NHANES) found that in-
creased urinary concentrations of MEP were associated
with increased blood pressure in children age 6 to
19 years (OR per log-unit increase:1.20; 95 % confidence
interval 1.01-1.43) [1]. In another study, higher urinary
Table 2 Adjusted difference in blood pressure (mmHg) at < 20 weeks of pregnancy, difference in highest blood pressure (mm Hg)
at≥ 20 weeks of pregnancy, and relative risk of pregnancy induced hypertensive disorders (gestational hypertension, preeclampsia,





















P-value RR of Pregnancy
Induced Hypertensive
Disorder (95 % CI)c
P-value
MEP-16 Weeks −0.1 (−1.3, 1.2) 0.91 0.8 (−1.1, 2.7) 0.40 1.1 (−0.3, 2.5) 0.13 1.0 (−1.2, 3.2) 0.36 1.16 (0.66, 2.05) 0.60
MBzP-16 Weeks 2.3 (0.9, 3.7) <0.01 1.9 (−0.3, 4.1) 0.08 1.4 (−0.5, 3.3) 0.15 1.3 (−1.4, 4.1) 0.35 1.74 (0.78, 3.89) 0.18
MCPP-16
Weeks
1.1 (−0.9, 3.2) 0.29 0.6 (−2.5, 3.6) 0.72 0.7 (−1.7, 3.0) 0.59 2.4 (−0.9, 5.7) 0.16 0.86 (0.33, 2.24) 0.76
∑DBP-16 Weeks 1.6 (−0.3, 3.5) 0.09 0.5 (−2.5, 3.6) 0.73 1.1 (−1.2, 3.5) 0.34 0.1 (−3.7, 3.8) 0.98 1.42 (0.53, 3.79) 0.48
∑DEHP-16
Weeks
−0.4 (−1.6, 0.8) 0.49 −0.2 (−2.0,
1.6)
0.85 −0.8 (−2.2, 0.5) 0.24 −1.0 (−3.0, 1.0) 0.35 0.85 (0.46, 1.58) 0.61
MEP-26 Weeks 1.0 (−0.4, 2.3) 0.16 0.2 (−1.7, 2.1) 0.83 1.17 (0.67, 2.05) 0.57
MBzP-26 Weeks 1.0 (−0.7, 2.8) 0.25 0.6 (−2.3, 3.4) 0.70 1.59 (0.82, 3.06) 0.17
MCPP-26
Weeks
0.1 (−2.5, 2.6) 0.97 −0.9 (−4.7, 3.0) 0.66 2.73 (1.07, 6.93) 0.04
∑DBP-26 Weeks 2.8 (0.4, 5.3) 0.02 2.7 (−0.9, 6.3) 0.14 2.11 (0.91, 4.90) 0.08
∑DEHP-26
Weeks
0.3 (−1.3, 1.9) 0.73 −0.8 (−3.1, 1.6) 0.52 1.42 (0.64, 3.13) 0.39
MEP-Average 1.4 (−0.2, 3.0) 0.09 0.8 (−1.6, 3.1) 0.53 1.14 (0.59, 2.18) 0.70
MBzP-Average 1.5 (−0.6, 3.6) 0.16 1.1 (−2.0, 4.3) 0.49 1.98 (0.96, 4.11) 0.07
MCPP-Average 0.6 (−2.4, 3.7) 0.69 1.1 (−3.3, 5.5) 0.62 1.67 (0.58, 4.82) 0.34
∑DBP-Average 2.8 (−0.1, 5.8) 0.06 1.7 (−2.7, 6.1) 0.45 2.49 (0.81, 7.65) 0.11
∑DEHP-Average −0.6 (−2.4, 1.3) 0.55 −1.6 (−4.3, 1.2) 0.27 1.09 (0.45, 2.66) 0.84
*-Adjusted for maternal race, maternal age at delivery, household income, education, marital status, serum cotinine concentration, weeks of gestation at blood
pressure measurement, parity, BMI at 16 weeks gestation, and previous use of blood pressure medications. The blood pressure models were additionally adjusted
for the week of pregnancy that the blood pressure measurement was taken
a-n = 369 with 719 repeated observations
b-n = 371 with 736 repeated observations for 16 weeks, n = 360 with 714 repeated observations for 26 weeks, and n = 374 with 742 repeated observations
for average
c-n = 366 for 16 week, 355 for 26 week, and 369 for average
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concentrations of the DEHP metabolite, MECPP in early
pregnancy (4.7-16.1 weeks) were associated with placen-
tal causes of preterm birth (OR 1.46; 95 % CI 1.1-1.95)
among US women [14]. In the same study, concentra-
tions of other phthalate metabolites, including MBzP
were associated with preterm birth, but when placental-
causes of preterm birth were examined separately, the
results did not reach statistical significance [14].
In our study, we did not find an association be-
tween MEP or DEHP and maternal blood pressure or
pregnancy-induced hypertensive disease. Only MBzP
showed a significant association with both increased dia-
stolic blood pressure and pregnancy-induced hypertensive
diseases. Serum MBzP has previously been associated with
cardiovascular disease risk factors in a study of elderly
adults from Sweden [2]. Individuals with higher serum
Fig. 2 Highest diastolic blood pressure >20 weeks gestation according to urinary MBzP tercile at 16 weeks of pregnancy (n = 371, 736 repeated
measurements). *- Adjusted for maternal race, age at delivery, household income, education, marital status, serum cotinine concentrations, parity,
BMI at 16 weeks gestation, previous use of medication for high blood pressure, and week of pregnancy that the blood pressure measurement
was taken
Fig. 1 Adjusted diastolic blood pressure at <20 weeks gestation according to urinary MBzP tercile at 16 weeks of pregnancy (n = 369, 719
repeated measurements). *- Adjusted for maternal race, age at delivery, household income, education, marital status, serum cotinine
concentrations, parity, BMI at 16 weeks gestation, previous use of medication for high blood pressure, and week of pregnancy that the blood
pressure measurement was taken
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concentrations of MBzP were more likely to have plaque
echogenicity and intima-media thickening and echogeni-
city. However, serum phthalate monoester biomarkers
could be subject to exogenous diester phthalate contamin-
ation, thus, making them inappropriate for epidemio-
logical studies [15]. It is plausible that similar subtle
changes in the vasculature of reproductive age women
could lead to slightly higher diastolic blood pressures and
an increased risk of pregnancy-induced hypertensive dis-
ease. Thus future studies using urinary biomarkers, which
are less susceptible to exogenous contamination, might
benefit from ultrasound assessment of the uterine arteries
in addition to biologic specimen and outcome collection.
This study has several limitations. While the HOME
Study collected a rich set of phthalate exposure bio-
markers from pregnant women, the primary outcome of
interest was not blood pressure or hypertensive disor-
ders of pregnancy. Thus, we relied on chart-derived
blood pressure measures rather than research quality
blood pressure measures. Blood pressures can be falsely
elevated if collected immediately after a patient enters
the clinic, after smoking tobacco or if the blood pressure
cuff is too small. In addition, we did not have detailed
information on the quality controls used to ensure ac-
curate blood pressures. However, this bias should be
non-differential with respect to phthalate exposure. An-
other limitation of this analysis is that we do not have
pre-pregnancy health status which may have contributed
to the risk of increased blood pressures and pregnancy
induced hypertensive diseases. We also evaluated five
different types of phthalate metabolites and there is a
chance of type I error due to multiple comparisons.
However, it seems unlikely that our MBzP associations
were spurious given that we saw consistent associations
between urinary MBzP concentrations and blood pres-
sure at two time points in pregnancy, as well as risk of
pregnancy-induced hypertensive diseases. Furthermore,
the MBzP concentration in the earlier pregnancy win-
dow (16 weeks rather than 26 weeks) was most strongly
tied to pregnancy induced hypertensive disorders. This
is consistent with the hypothesis that some pregnancy
induced hypertensive disorders are the end result of an
Table 3 Adjusted difference in blood pressure (mmHg) at < 20 weeks of pregnancy, difference in highest blood pressure (mm Hg)
at≥ 20 weeks of pregnancy, and relative risk for pregnancy-induced hypertensive disease (gestational hypertension, preeclampsia,










Diastolic BP at <20
Weeks (95 % CI) a
Difference in
Systolic BP at <20
Weeks (95 % CI) a
Difference in
Diastolic BP at ≥20
Weeks (95 % CI)b
Difference in
Systolic BP at ≥20
Weeks (95 % CI)b
RR for pregnancy-
induced hypertensive
disease (95 % CI)c
16 Week-1st 6/122 3.9 (0.5, 6.5) Ref Ref Ref Ref Ref
16 Week-2nd 8/122 9.8 (6.5, 13) 0.5 (−1.1, 2.1) −1.0 (−3.4, 1.5) 0.6 (−1.2, 2.4) −0.3 (−3.0, 2.4) 1.44 (0.51, 4.02)
16 Week-3rd 19/122 22 (13, 331) 2.2 (0.5, 3.9) 2.1 (−0.5, 4.7) 2.8 (0.9, 4.7) 2.3 (−0.3, 4.9) 2.92 (1.15, 7.41)
P-value for
trend
<0.01 0.05 <0.01 0.05 0.01
26 Week-1st 10/118 3.9 (0.1, 6.0) Ref Ref Ref
26 Week-2nd 7/119 9.0 (6.1, 14) 0.9 (−1.0, 2.9) 1.0 (−1.8, 3.8) 0.91 (0.35, 2.42)






8/123 4.5 (0.2, 6.4) Ref Ref Ref
Pregnancy
Average-2nd
9/123 9.0 (6.4, 13) 1.0 (−0.8, 2.8) 1.1 (−1.5, 3.8) 1.30 (0.55, 3.09)
Pregnancy
Average-3rd




*- Adjusted for maternal race, age at delivery, household income, education, marital status, serum cotinine concentrations, parity, BMI at 16 weeks gestation, and
previous use of medication for high blood pressure. The blood pressure models were additionally adjusted for the week of pregnancy that the blood pressure
measurement was taken
a-n = 369 with 719 repeated observations
b-n = 371 with 736 repeated observations for 16 weeks, n = 360 with 714 repeated observations for 26 weeks, and n = 374 with 742 repeated observations
for average
c-n = 366 for 16 week, 355 for 26 week, and 369 for average
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abnormal spiral artery invasion between mother and
fetus that develops prior to 16 weeks gestation [16].
The generalizability of these findings might be lim-
ited since our study participants were at lower-risk of
pregnancy-induced hypertensive disorders then most
obstetric populations. However, urinary phthalate con-
centrations among women in this cohort were similar
to nationally-representative samples of women in the
US [17]. Additionally, while we have sensitive and
specific biomarkers of phthalate exposure from two
time points during pregnancy, urinary phthalate me-
tabolite concentrations exhibit moderate to high vari-
ability within individuals due to their relatively short
biological half-life (<24 h) and the episodic nature of
exposure. To the extent that phthalate exposures were
misclassified, our results would be biased toward the
null. Finally, while we can speculate on the mechan-
ism by which phthalate concentrations impact blood
pressure and pregnancy induced hypertensive diseases,
we do not have data on the cytokine markers of in-
flammation or other relevant biological pathways.
This study has several strengths. First, it is a prospect-
ive cohort study that enrolled women in early pregnancy
to investigate the impact of environmental chemicals. In
addition, we made every effort to minimize exogenous
contamination of our samples and quantified urinary
levels of phthalate metabolites using state of the art ana-
lytic chemistry methods. This is particularly important
because the parent phthalate diesters may be found in
specimen collection materials and other medical equip-
ment, thus potentially contaminating the samples [18].
By examining the metabolized phthalate monoesters, we
minimized the potential for this exogenous contamin-
ation. Second, we collected two measures of phthalate
metabolites during pregnancy, which allowed us to re-
duce some of the within-person variation of these expo-
sures and examine distinct windows of vulnerability.
Finally, we controlled for numerous confounders includ-
ing biomarkers of other environmental exposures, such
as serum cotinine and serum lead concentrations that
are often not available in other studies. However, it is
possible that other chemicals in products containing
BBzP (the parent diester of MBzP) may be responsible
for some or all of the association between urinary MBzP
concentrations and blood pressure or blood-pressure re-
lated complications.
Conclusions
In this cohort, we observed that higher urinary MBzP
concentrations were associated with both elevated ma-
ternal diastolic blood pressure and increased risk of
pregnancy-induced hypertensive diseases. While expos-
ure to MBzP’s parent compound, BBzP, is nearly univer-
sal among pregnant women, exposure could be
prevented. Thus, it is vital that additional studies more
thoroughly evaluate how, and when phthalates can affect
maternal and fetal health.
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